About Circle Pharma
Circle Pharma is a Healthcare company based in San Francisco (United States) founded in 2014. It operates as a macrocycle therapeutics are developed for cancer and serious illnesses. It operates on a HealthTech model. Circle Pharma has raised $302.75 million across 8 funding rounds from investors including Lilly, Pfizer and The Column Group. The company has 50 employees. Circle Pharma offers products and services including MXMO™ Platform and Cancer Therapies. Its focus areas include Biotechnology and Cancer Therapeutics. Its competitors include Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
Circle Pharma is engaged in the development of innovative cancer therapies using macrocycles. The proprietary MXMO platform is utilized to target undruggable proteins, aiming to transform cancer treatment experiences. Solutions are designed to offer enhanced selectivity, potentially reducing side effects for patients. The company operates within the biotechnology sector, contributing to advancements in cancer care through clinical trials and research publications.
- Headquarters San Francisco, United States
- Employees 50
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website circlepharma.com
- Social LinkedIn X
- Legal Name Circle Pharma
- Total Equity Funding$302.75M (USD)
in 8 rounds
- Latest Funding Round$92.5M (USD), Series E
Sep 2026
- InvestorsLilly
& 14 more
- Employee Count50
Products & Services of Circle Pharma
Circle Pharma offers a comprehensive portfolio of products and services, including MXMO™ Platform and Cancer Therapies.
Macrocycle platform is developed for targeting undruggable proteins.
Cancer therapies are created using selective macrocycle technology.
Funding Insights of Circle Pharma
Circle Pharma has successfully raised a total of $302.75M across 8 strategic funding rounds. The most recent funding activity was a Series E round of $92.5 million completed in September 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $302.75M
- Total Rounds 8
- Last Round Series E — $92.5M
- Investors Count 15
All 8 funding rounds of Circle Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2026 | $92.5M | Series E | – | The Column Group | |
| Jun 2024 | $92.44M | Series D | – | TCG | |
| Jun 2021 | $66.3M | Series C | – | TCG, Nextech Invest | |
| Mar 2020 | $45M | Series B | – | TCG | |
| Apr 2017 | $2M | Series A | – | WI Harper Group, Element Partners | – |
| Sep 2016 | $4.5M | Series A | – | Mission Bay Capital | |
| Jan 2016 | – | Seed | – | – | |
| Sep 2014 | – | Seed | – | Pfizer |
15 investors in total: 15 institutional.
Investors in Circle Pharma
Circle Pharma has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, Pfizer and The Column Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage investments in US life science startups are focused on. | 2007 | thecolumngroup.com | San Francisco, United States | |
PE firm investing in the US | – | nextechinvest.com | Zurich, Switzerland | |
Multiple sectors are invested in by this single-family office. | – | euclideancapital.tcc.mode | New York, United States | |
Early-stage biotech funding and support are provided by Pandect Bioventures. | – | pandectbio.com | South San Francisco, United States | |
Growth-stage companies are invested in by this venture capital fund. | – | pavilioncapital.com | New York, United States | |
- | – | berkeleycatalystfund.com | - | |
Venture capital firm focused on healthcare startups | – | lifeforcecap.com | San Francisco, United States | |
- | – | shangpharmainnovation.com | - | |
VC firm that does investment in early stage companies in the US & China | 1993 | wiharper.com | San Francisco, United States | |
- | – | elementpartners.com | - |
Investor details for Circle Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Circle Pharma
9 people are tracked at Circle Pharma (6 in leadership, 1 in board & advisors, 2 in team); the tracked headcount is 50.
| Name | Role | Group |
|---|---|---|
Paul Park | Chief Business Officer | Leadership |
Linda Bergstedt | Executive Director & Head, People | Leadership |
David J. Earp | President & CEO | Leadership |
Edward Garmey | Interim Chief Medical Officer | Leadership |
Sabrina Deltoro | Head Of Talent (via Delson Talent) | Leadership |
Joyce Liao | Vp, Business Development & Alliance Management | Leadership |
Zaneta Nikolovska–Coleska | Advisor | Board & advisors |
Eleonor Lim | Executive Assistant | Team |
Stacey Mendoza | HR Operations Specialist | Team |
Complete people profiles for Circle Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Circle Pharma
3 dated milestones of Circle Pharma across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Circle Pharma is founded.
- Funding First funding round.
- Funding Latest funding round, Series E, of $92.5M.
Competitors of Circle Pharma
Circle Pharma has 9 listed competitors in our database, 8 of them funded. They include Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| adacap.com | 2002 | Saint Genis Pouilly, France | $56.13M | – | Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. |
Detailed competitors of Circle Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Circle Pharma
The website of Circle Pharma (circlepharma.com) receives about 2.8K visits a month.
- Monthly visits2.8K
▲ 32.5% vs previous month
Websites whose visitors overlap most with Circle Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| r2mpharma.com | 100% | 2.9K | #4,331,217 | View details | |
| astellasgenetherapies.com | 100% | 1K | – | View details | |
| theranova.com | 96% | – | – | View details | |
| corvuspharma.com | 96% | 13.6K | #3,366,661 | View details | |
bplifescience.com | bplifescience.com | 95% | – | – | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 31 similar websites and full traffic analytics for Circle Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 31 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
10 companies that operate in the same segment as Circle Pharma (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Circle Pharma
Complete news archive for Circle Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Circle Pharma
Circle Pharma was founded in 2014.
Circle Pharma is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Circle Pharma is a funded company, having raised a total of $302.75M across 8 funding rounds to date.
Circle Pharma has 50 employees.
Circle Pharma is engaged in the development of innovative cancer therapies using macrocycles. The proprietary MXMO platform is utilized to target undruggable proteins, aiming to transform cancer treatment experiences. Solutions are designed to offer enhanced selectivity, potentially reducing side effects for patients. The company operates within the biotechnology sector, contributing to advancements in cancer care through clinical trials and research publications.
Circle Pharma's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Circle Pharma offers MXMO™ Platform and Cancer Therapies.
Circle Pharma has 15 investors. Key investors include Lilly, Pfizer, The Column Group, WI Harper Group, and Hartford Hospital.
Circle Pharma operates through Circle Pharma.